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24The  increasing  incidence  of diseases  affecting  the  central  nervous system 
 
25(CNS)  demands the  urgent   development  of  efficient  drugs.   While  many  of 
 
26these medicines are  already available, the Blood Brain Barrier and  to a lesser 
 
27extent, the  Blood Spinal Cord  Barrier  pose physical and  biological limitations 
 
28to their diffusion to reach target  tissues. Therefore, efforts are  needed not only 
 
29to  address drug  development  but  specially  to  design suitable  vehicles  for 
 
30delivery  into  the  CNS  through  systemic  administration.  In the  context  of the 
 
31functional   and   structural   versatility   of  proteins,   recent  advances  in   their 
 
32biological  fabrication  and  a  better   comprehension  of  the  physiology  of  the 
 
33CNS offer a plethora of opportunities for the construction and  tailoring of plain 
 
34nanoconjugates and  of more  complex nanosized vehicles able to cross these 
 
35barriers. We revise here  how the engineering of functional proteins offer drug 
 
36delivery tools for specific CNS diseases and  more  transversally, how proteins 
 
37can   be  engineered  into  smart  nanoparticles  or  ‘artificial  viruses’  to  afford 
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441. Introduction 
45         The  maintenance of the  central nervous system (CNS) homeostasis is 
 
46essential for its normal function. The  limits of the  CNS  tissue are  established 
 
47by the astrocytic glia limitans facing the meninges and  the blood vessels, and 
 
48by the  ependimocytes  of the  choroid  plexus  were  the  cerebrospinal  fluid is 
 
49produced (Figure 1 A). Astrocyte  end-feet wrap the meningeal fibroblasts and 
 
50the   endothelial   cells   (ECs)   of  the   capillaries,   leaving  between  them   the 
 
51basement membrane. Brain  capillaries  display  a  large  surface  area (~20  m 2 
 
52per 1.3 kg brain), and  thus possess a predominant role in regulating the brain 
 
53microenvironment.  The  blood-brain-barrier  (BBB)  limits  the  entry  of  blood- 
 
54derived   molecules   and   circulating   leukocytes,   protecting   the   CNS   from 
 
55fluctuations    in    plasma    compositions    or    circulating    agents   such     as 
 
56neurotransmitters and  xenobiotics.  It  is  composed of specialized  ECs held 
 
57together  by  multiprotein  complexes   known   as tight  junctions,   astrocytes, 
 
58pericytes and  basement membrane (Abbott et al. 2006;  Reese and  Karnovsky 
 
591967)  (Figure 1 B). CNS  ECs display more  efficient cell-to-cell tight junctions 
 
60than  other  ECs (Wolburg and  Lippoldt 2002),  rest  on a continuous basement 
 
61membrane and  express a series of transporters responsible for the  regulated 
 
62exchange  of  nutrients and   toxic  products. These  characteristics  make   the 
 
63CNS   ECs  a   continuous   and    selective   physical   barrier   for   hydrophilic 
 
64substances, and  a key player in the regulated trafficking of molecules into the 
 
65CNS  (Abbott  et  al.  2006)   (Figure  2).  Interestingly,  the  Blood  Spinal  Cord 
 
66Barrier  (BSCB)  displays  similarities  to the  BBB, but it also  has some unique 
 
67properties,  among  them   being  slightly  more   permeable   (Bartanusz  et  al. 
 
682011).  Transit restrictions imposed by the BBB (and at lesser extent  by BSCB) 
 
69represent the  most  important  barrier  to overcome in  the  drug  delivery  to the 
 
70CNS.  In the context  of emerging neurological diseases, targeting drugs to the 
 
71CNS is under  strong  pushing demands, but vehicles for BBB crossing are  still 
 
72in their infancy, with a long run until full tailoring. 
73 
742. Cross-transportation through BBB 
75         The  BBB gradually develops in humans during the  first postnatal year 
 
76(Adinol 1979)  and  its nearly complete in rats after the second postnatal week 
 
77(Stewart and  Hayakawa 1987).  This  highly  differentiated  EC  phenotype  is 
 
78induced and  maintained in the  long term  by interactions with the  surrounding 
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79cells, mainly astrocytes and  pericytes but also perivascular macrophages and 
 
80even   neurons (Abbott  et  al.  2006;  Alvarez  et  al.  2011;  Arthur  et  al.  1987; 
 
81Janzer  and   Raff   1987).   For   instance,   in   vivo,   astrocytes  secrete  Sonic 
 
82Hedgehog (Shh),  that  will act  on endothelial cells and  promote BBB integrity 
 
83(Alvarez et al. 2011).  In addition to the  role in long-term barrier induction and 
 
84maintenance,  astrocytes and  other  cells  can  release  chemical  factors  that 
 
85modulate   local   endothelial   permeability  over   a  time-scale   of  seconds  to 
 
86minutes.  Thus,   both  natural  stimuli  for  BBB  leakage  and   pharmacological 
 
87compounds acting on endogenous BBB induction pathways like Shh  inhibitors 
 
88(Alvarez  et  al.  2011)   can  be  used to  transiently  increase  the  entrance of 
 
89molecules    into    the     CNS     parenchyma.    Moreover,   the     phenotypical 
 
90characteristics of the BBB ECs includes both uptake mechanisms (e.g.  GLUT- 
 
911 glucose  carrier,  L1 amino  acid  transporter, transferrin receptor) and  efflux 
 
92transporters  (e.g.   P-glycoprotein),   and   thus  transporter/receptor-mediated 
 
93transit   across  the   BBB   has  also   been  used  to   deliver   molecules   of 
 
94pharmacological  interest  into  the  CNS  parenchyma (Figure  2).  In this  case, 
 
95specific transcellular receptor-mediated transcytosis transport molecules from 
 
96the   luminal  membrane,  lining  the   internal  surface  of  the   vessels,  to  the 
 
97abluminal  membrane  on  the  external  CNS-lining  surface.  In  addition,  less 
 
98specific adsorptive-mediated transcytosis can  also be  used for the delivery of 
 
99molecules,  but  CNS  ECs  show   a  lower  rate   of  transcytosis  activity  than 
 
100peripheral   ECs  (Rubin   and   Staddon  1999),   making   this   a   less   efficient 
 
101process for the incorporation of circulating molecules.
102 A final consideration regarding potential limiting steps for the delivery of
 
103hydrophilic substances into the  CNS  across the  BBB is that  both  intracellular 
 
104and extracellular enzymes provide an additional barrier.  Extracellular enzymes 
 
105such  as peptidases  and  nucleotidases  are  capable  of metabolizing  peptides 
 
106and  ATP respectively. Intracellular enzymes, that  are  involved in hepatic drug 
 
107metabolism,  have   been  found  in  the   small  microvessels  from  brain,  the 
 
108choroid plexuses, and  the leptomeninges (pia plus arachnoid mater),  such  as 
 
109monoamine  oxidase  and  cytochrome  P450,   and  they  can  inactivate  many 
 
110lipophilic neuroactive and toxic compounds (el-Bacha and Minn 1999).
111 The   delivery   of  substances  across  the   Blood   Cerebrospinal   Fluid
 
112Barrier  (BCFB) may  also be  considered as an  interesting option. This barrier 
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113shows a  morphological  correlate  with  the  BBB at  the  level  of tight  junctions 
 
114between the cells. These, however, are  not located at the ECs capillaries that 
 
115are  in fact fenestrated (Figure 1 C), but on the  apical surface of the epithelial 
 
116cells  of  the  choroid  plexus  and   the  arachnoid  fibroblasts  along  the  blood 
 
117vessels,  inhibiting  paracellular  diffusion  of hydrophilic  molecules  across this 
 
118barrier.  When   a  substance  reaches  the   cerebrospinal  fluid  it  can   diffuse 
 
119through   the  Virchow-Robin's  perivascular  spaces  (Bechmann et  al.  2001), 
 
120which  are  located  between the  basement  membrane around pericytes  and 
 
121ECs and  the  basement membrane at  the  surface  of the  glia  limitans  of the 
 
122brain  vessels  (Figure  1 B). These perivascular  spaces are  in  direct  contact 
 
123with  the  subarachnoid  space and  thus with  the  cerebrospinal  fluid.  When 
 
124small tracers are  injected into the cerebrospinal fluid they follow the fluids flow 
 
125through  the  perivascular  spaces and  the  ventricles, and  they  may  enter  the 
 
126brain  parenchyma (Iliff  et  al.  2012).  In fact,  after  an  intracisternal  injection, 
 
127small  hydrophilic  molecules  can  be  observed around the  ventricle  walls  and 
 
128the superficial layers of the CNS in contact with the meninges or in the whole 
 
129brain  parenchyma depending  on  the  size  of the  molecule  (Iliff  et  al.  2012). 
 
130Larger  molecules will not enter  the  brain parenchyma after intraventricular or 
 
131intracisternal injection due  to the ependymocytes and  the  glia limitans and  its 
 
132basal  lamina  (Bechmann et al. 2001;  Iliff et al. 2012;  Kim et al. 2006) , being 
 
133only   observed  in   the   perivascular   compartment.  Thus,   after   intravenous 
 
134administration, a hydrophilic drug  will not reach the  cerebrospinal  fluid, but if 
 
135administered  intracisternaly  it  may  enter   the  brain  parenchyma in  a  size- 
 
136depending  fashion.  The  engineering  of appropriate  vehicles  for cargo   drug 
 




1403. Disturbed BBB permeability
141 BBB disruption is a central and  early  characteristic of many  acute and
 
142chronic  CNS  injuries  such   as stroke,   trauma,  inflammatory  and   infectious 
 
143processes, Multiple Sclerosis, Alzheimer, Parkinson, epilepsy, pain, and  brain 
 
144tumors  (Abbott et al. 2006;  Rosenberg 2012).  In these cases, the  increase in 
 
145BBB permeability is  linked  to the  dysfunction of the  CNS  (Rosenberg 2012). 
 
146For  instance,  inflammation  is  a  common feature  of both  chronic  and  acute 
 
147CNS  injuries  and   it  is  one   of  the  main  causes  of  the  expansion  of  the 
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148neuropathology to adjacent CNS tissue areas. Many inflammatory mediators, 
 
149like  tumor  necrosis factor-α  (TNFα),  induce  BBB permeability  acting  directly 
 
150on ECs (Deli et al. 1995)  or indirectly by activating astrocytes to secrete other 
 
151proinflammatory  mediators  like  IL-1β  (Didier  et  al.  2003),   and  in  this  way 
 
152contribute  to  the  disease  severity.  In  the  Multiple  Sclerosis  model  termed 
 
153Experimental  Allergic  Encephalomyelitis  (EAE),  the   major  BBB  disruption 
 
154occurs  in  white  matter   post-capillary  venules  in  response to  inflammatory 
 
155stimuli   (Tonra   2002),   showing   that   these  locations   can   also   constitute 
 
156important places for the entry of circulating molecules and  cells into the brain. 
 
157After a  traumatic  brain  injury  there  is  a  rapid  extravasation  of blood  in  the 
 
158central   damaged  areas,   and    intravascular   coagulation   and    significant 
 
159reduction in blood flow in the  pericontusional brain areas. This is followed by 
 
160two  peaks  of  BBB  opening   at  4-6  hours   and   2-3  days  after   the   insult 
 
161(Chodobski  et  al.  2011).  Thus,  though  the  extent  and  particular  moments of 
 
162BBB  permeability  varies  in  the  different  pathologies,  it  can  be  used as a 
 
163therapeutic time-window to deliver molecules into the CNS (Rosenberg 2012).
164 Transient pharmacological stimulation of BBB opening for drug delivery
 
165is  tempting,  and  it can  be  achieved  by the  injection  of hypertonic  solutions 
 
166with    Mannitol.    However,   the    potential    toxic    effects,    especially    under 
 
167pathological conditions, are  notable. Though  the permeability of the BBB may 
 
168be   spontaneously  enhanced  at   certain   time-windows   post-injury,   as  for 
 
169example  after Traumatic  Brain  or Spinal  Cord  Injury  (Bartanusz et al.  2011), 
 
170that   will  allow  the   desired  drugs  entering  the   CNS,   the   pharmacological 
 
171disruption  of the  BBB under  pathological  conditions  may  in  contrast worsen 
 
172the  disease  progression. For instance,  the  pharmacological  disruption  of the 
 
173BBB enhanced the  clinical  severity in  an  EAE  model  (Alvarez  et  al.  2011), 
 
174indicating that the integrity of the BBB is involved in the pathology and  it also 
 
175modulates the recovery. In this context, the dysfunction of the BBB and  BSCB 
 
176has been  well  documented in  the  etiology  or  progression of  several  CNS 
 
177pathologies (Bartanusz et al. 2011),  making  the  enhancement of BBB barrier 
 
178permeability  not  indicated  for the  delivery  of drugs into  the  damaged CNS. 
 
179Again, specific BBB crossing vehicles would be  required to provide the drugs 
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1824. Viral and viral-based vectors for BBB crossing
183 Recent reports have  demonstrated that  some non-pathogenic,  single-
 
184stranded DNA human parvoviruses,  in  particular  the  adeno-associated virus 
 
185(AAV)  serotypes  6   and    9,   enter    the   CNS   following   intravenous   (i.v.) 
 
186administration without the use of any BBB-permeabilizing agents (Duque  et al. 
 
1872009;   Foust   et   al.   2009;   Foust   et   al.   2010;   Towne   et   al.   2008) .  This 
 
188observation  generated important  expectations  regarding  the  identification  of 
 
189surface  protein  motifs  capable  of  inducing  transport of  vectors across  the 
 
190BBB.
191 Recombinant vectors for AAV-derived gene therapy (rAAVs) can  infect
 
192a broad  range of both dividing and  post-mitotic cells, and  their DNA persists in 
 
193an episomal state thus enabling efficient and  stable transduction  (Grieger  and 
 
194Samulski 2005;  Mandel et al. 2006).  These vehicles are  highly efficient in the 
 
195nervous system and  infect mainly neurons by intrathecal (Federici et al. 2012) 
 
196or intracerebral  injections  (Burger  et  al.  2005;  Mandel  et  al.  2006;  McCown 
 
1972005).   Towne   and   colleagues   (Towne   et  al.   2008)   observed  that   motor 
 
198neurons could  be  transduced along  the  entire  spinal  cord  through  a  single 
 
199noninvasive   i.v.   delivery   of  rAAV6  in   42   days  old   wt  and   SOD1   G93A 
 
200transgenic  mice  model  of Amyotrophic  Lateral  Sclerosis. The  transduction  of 
 
201astrocytes and  other  non-motor neuron cells,  along  with  the  finding  that  the 
 
202motor    neurons   were    not   transduced   following   intramuscular   injection, 
 
203suggested that the mechanism of transduction was independent of retrograde 
 
204transport, and  that  the  vector  was in fact able to cross the  BBB (Towne  et al. 
 
2052008).  Moreover,  rAAV9 were  found to be very efficient for transducing spinal 
 
206cord cells including motor neurons after i.v. delivery in both neonate and  adult 
 
207mice  (Duque  et  al.  2009).  Kaspar and  colleagues  (Foust  et  al.  2009)  have 
 
208demonstrated that  delivery of rAAV9 through  the  systemic circulation lead  to 
 
209widespread  transduction  of the  neonatal  and  adult  mice  brain,  with  marked 
 
210differences   in   cell   tropism   in   relation   to  the   stage  of  development   and 
 
211complexity  of the  BBB (Foust  et al.  2009;  Lowenstein  2009).  In accordance, 
 
212Gray  and   colleagues  (Gray  et  al.  2011)   reported  the  ability  of  rAAV9 to 
 
213transduce neurons and  glia  in  the  brain  and  spinal  cord  of adult  mice  and 
 
214nonhuman primates.  They  suggest that  AAV9 enters the  nervous system by 
 
215an active transport mechanism across the BBB rather  than by passive slipping 
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216through  the tight junctions between endothelial cells, as the co-administration 
 
217of mannitol  prior to rAAV injection  resulted  in  only  a  50  % increase  in  brain 
 
218delivery. They observed extensive transduction of neurons and glia throughout 
 
219the mice brain and  spinal cord (with neurons outnumbering astrocytes ~ 2:1 in 
 
220the  hippocampus  and  striatum  and  1:1  in  the  cortex).  However,   the  overall 
 
221transduction efficiency was considerably lower in non-human primates, being 
 
222glial  cells  the  main  cell  type  transduced. These rodent/non-human primate 
 
223differences are  important for clinical applications, and  may reflect a variety of 
 
224species-specific factors including differential BBB transport, capsid-interacting 
 
225blood  factors  to  promote or  inhibit  rAAV9 transduction,  neural  cell  tropism 
 
226within  the   brain,  and/or   intracellular  trafficking  and   vector   persistence.  A 
 
227summary of the AAV9 viral-based  administration strategies  to cross the  BBB 
 
228for  therapeutic   purposes  is   summarized   in   Figure   3.   Nevertheless,   the 
 
229identification of the functional motifs of the surface proteins of AVV6 and AVV9 
 
230will  surely  contribute  to  the  engineering  of  more   effective  vectors  for  the 
 
231treatment of central nervous system injuries. In fact, AAV capsid DNA shuffling 
 
232and  subsequent directed evolution generated AVV novel clones able to cross 
 




236 Obviously, in the context  of biological risks associated to administration
 
237of viruses  (Edelstein  et  al.  2007)  and  the  inflammatory  conditions  linked  to 
 
238AVV  administration   and    immune   responses   (Daya    and    Berns   2008), 
 
239molecular carriers or non-infectious virus-inspired constructs (artificial viruses) 
 
240would   be   preferred   for   drug   BBB-cross   delivery.   Artificial   viruses   are 
 
241nanostructured, manmade  molecular  oligomers  that  mimic  viral  behaviour 
 
242regarding cell penetrability, targeted delivery of associated drugs and  nucleic 
 
243acids and  other  key functions relevant to encapsulation, cell surface receptor 
 
244targeting, intracellular trafficking and  eventual nuclear delivery, among others 
 
245(Mastrobattista et al. 2006).  In this regard, peptides and  proteins are  enough 
 
246versatile   to   functionalize   these  vehicles,   or   the   drug   itself   in   simpler 
 
247nanoconjugates. When  the  building blocks of drug  carries are  proteins, these 
 
248functions can  be  recruited by the  incorporation, in a single polypeptide chain, 
 
249of  functional  peptides  from  diverse  origins  that   supply  desired  biological 
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250activities  to  the  whole  construct  (Ferrer-Miralles  et  al.  2008;  Neus Ferrer- 
 
251Miralles et al. 2013; Vazquez et al. 2008; Vazquez et al. 2009). Also, principles 
 
252for  the   rational   control   of  self-assembling   of  natural   and   fully  de   novo 
 
253designed  polypeptides  as  nanostructured materials  are   being  established 
 
254(Domingo-Espin  et  al.  2011;  Unzueta et  al.  2012a; Unzueta et  al.  2012b; 
 
255Unzueta et al. 2013;  Vazquez et al. 2010;  Vazquez and  Villaverde 2010) , thus 
 
256opening a plethora of possibilities for the  design and  biological production of 
 
257nanostructured,  protein-based  artificial  viruses  (Neus  Ferrer-Miralles  et  al. 
 
2582013;   Rodriguez-Carmona  and   Villaverde   2010;   Vazquez   and   Villaverde 
 
2592013)  with  good  clinical  grade formulation  profile. The  BBB-crossing abilities 
 
260of AAVs prove,  in  any  case, the  potential  penetrability  of nanosized protein 
 
261entities in the context  of emerging nanomedicines of CNS. 
262 
 




From a different angle, chemical modification of a drug can  enhance its
 
265penetrability  into  the  CNS,  for example  by adding  domains  for glycosylation 
 
266(Poduslo   and   Curran   1992),   methylation   (Hansen,  Jr.   et   al.   1992)   and 
 
267pegylation  (Witt et al. 2001),  lipophilic domains  (Egleton and  Davis 2005),  or 
 
268coating it with polysorbates  (Bhaskar et al. 2010).  Also, precursors can  cross 
 
269the  BBB when  the  drug  cannot, as is the  case of L- Dopa  in the  treatment of 
 
270Parkinson's disease  (Wade  and  Katzman 1975).  In a  very  different  context, 
 
271adequate engineering of natural proteins can  offer, at different extents, tools to 
 
272functionalize free drugs or nanosized carriers to reach the  CNS  parenchyma 
 
273(Table  1).  For  that,  receptor-mediated  transcytosis can  be  reached by  the 
 
274incorporation  of  proteins  or  short   peptides  that  act  as ligands  of  insulin, 
 
275transferrin  or   low   density   lipoprotein   receptors  (Table   1).   For   instance, 
 
276monoclonal  antibodies  covalently  bound   to  therapeutic  proteins  have   been 
 
277targeted to insulin and  transferrin receptors (TfRs) in both  in vitro and  in vivo 
 
278models (Fu et al. 2010b;  Fu et al. 2011;  Lu et al. 2011) . In these experiments, 
 
279recombinant  proteins  have   two  functional  moieties;  the  therapeutic  peptide 
 
280fused to the carboxy  terminus of the IgG heavy  chain and  the complementarily 
 
281determining  regions  of the  monoclonal  antibodies  that  are  located  at  the  N- 
 
282terminus  (Pardridge   and   Boado    2012).   This   delivery   platform,   dubbed 
 
283Molecular   Trojan   Horse   and   extensively   exploited   by  Pardridge’s   group 
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284(Pardridge  2006),  can  be  adapted to any  therapeutic  protein  as long  as its 
 
285production in recombinant  organisms  maintains  its biological  function.  In this 
 
286context,  recent insights in industrial-oriented metabolic engineering (Lee et al. 
 
2872012)   and   the   wide   diversity   of  microbial   species  that   are   now   under 
 
288exploration  as cell  factories  for therapeutic  proteins  (Corchero et  al.  2013), 
 
289offer alternatives to conventional hosts for the  production of highly functional 
 
290protein  species.  In addition,  monoclonal  antibodies  conjugated  to  polymeric 
 
291micelles  (Yue  et  al.  2012),   liposomes  (Mamot  et  al.  2005;   Schnyder  and 
 
292Huwyler 2005b;  Zhang  et al. 2002)  and  polymeric nanoparticles (Reukov  et al. 
 
2932011a) can  improve the  performance of the  chemical entities in the  transport 
 
294of  therapeutic  molecules  across the  BBB.  Recent results  suggest that  low 
 
295affinity  binding  and  monovalent  binding  to  the  cellular  receptors are  highly 
 




In   the    development    of   photothermal    therapy,   gold    nanoparticles
 
298conjugated to peptides carrying the motif THR target  transferrin receptor (TfR) 
 
299and  they  are  delivered  to  the  CNS  (Prades et  al.  2012b). Also,  pegylated 
 
300Fe3O4  nanoparticles conjugated with lactoferrin (Qiao et al. 2012b)  have  been 
 
301proposed as MRI molecular probes for imaging diagnostic purposes. In some 
 
302instances,   intravenously   administered   nanoparticles   of  different   chemical 
 
303origin   get   adsorbed  to  apolipoproteins   and   the   entrance  to  the   CNS   is 
 
304mediated by low density  lipoprotein receptors (Gessner et al. 2001;  Kim et al. 
 
3052007).  This is the  case of human serum albumin nanoparticles (HSA) loaded 
 
306with   loperamide   (Ulbrich   et   al.   2011a).  Therefore,   some  nanoparticulate 
 
307carriers have  been modified to include low-density lipoproteins (LDL) or LDL 
 
308receptor binding peptides (ApoB (Spencer and  Verma  2007); APoE (Re et al. 
 
3092011;  Wagner et al.  2012)  and  Apo A-I (Fioravanti  et al.  2012;  Kratzer  et al. 
 
3102007a)) in their formulation, which results in significantly improved entrance to 
 
311the   brain  parenchyma  when   compared  with  naked  nanoparticles.  In  that 
 
312sense, HSA nanoparticles  with  covalently bound  ApoA-I or ApoE are  able  to 
 
313transport drugs  to  the  brain  with  similar  efficiency  as HSA  nanoparticles 
 
314conjugated  to  antibodies  against  insulin  or  transferrin  receptors,  or  HSA 
 
315nanoparticles  conjugated  to insulin  or transferrin (Zensi  et al.  2009;  Zensi  et 
 
316al. 2010).  Among successful examples, peptides derived  from the  consensus 
 
317binding   sequence  (Kunitz   domain)   of  proteins   transported  through   LDL 
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318receptors, such  as aprotinin  and  Kunitz  precursor inhibitor  1 (Demeule  et al. 
 
3192008b;   Gabathuler  2010b), must  be  stressed as very  promising  (Table  1). 
 
320Kunitz-derived  peptides  (angiopeps),  covalently  bound  to  drugs,   have  been 
 
321already used or are  in ongoing clinical trials for the treatment of brain tumors. 
 
322The main objective of the targeting peptides in clinics is the treatment of brain 
 
323metastases from  solid  tumors  (breast and  lung  cancers) as an  alternative  to 
 
324the  surgical  removal  of  the  primary  brain  tumor.  Particularly,  it  has been 
 
325demonstrated that  angiopep conjugated to paclitaxel (ANG1005,  also named 
 
326GRN1005,                                  http://clinicaltrials.gov/ct2/show/NCT01480583? 
 
327term=ANG1005&rank=6), is well tolerated and  shows activity in patients with 
 
328advanced solid tumors  previously treated with antitumor drugs (Kurzrock et al. 
 
3292012).  In addition, there  are  three  ongoing clinical trials in the  same direction 
 
330(http://clinicaltrials.gov).  Apart  from  the  endogenous ligands,  other  peptides 
 
331with high affinity for brain receptors (or strong  cell-penetrating peptides) have 
 
332also   been  explored   as  functional   materials,   including   pegylated-gelatin 
 
333siloxane  nanoparticles  conjugated  with  HIV-1-derived Tat peptide  (Tian  et al. 
 
3342012),  rabies  virus  glycoprotein  conjugated  to  liposomes  (Tao  et  al.  2012), 
 
335variable  heavy-chain  domain  of camel  homodimeric  antibodies  (VHH) (Li  et 
 
336al.,   2012)    for   receptor-homing   peptides   obtained   from   phage  display 
 
337screening  (Maggie  et  al.  2010;  Malcor  et  al.  2012).  To  gather all  published 
 
338information related to peptides with activity to cross the  BBB, Van Dorpe  and 
 
339collaborators  designed  a  peptide  database to organize  scattered information 
 
340(Van et al. 2012)  (http://brainpeps.ugent.be). The main approaches to protein- 
 








Among  CNS  diseases, only three  are  currently treated with drugs that
 
345naturally   cross  the   BBB,  namely   epilepsy,   chronic   pain   and   psychiatric 
 
346disorders (Ghose et al. 1999).  For degenerative diseases, vascular diseases, 
 
347trauma aftermaths,  viral  infections  and  congenital  diseases  occurring  in  the 
 
348CNS,  there  is  a  pushing  need to  develop  BBB-crossing strategies  for drug 
 
349delivery,   preferentially   based  on   non-viral   carriers  (Table   2).   The   most 
 
350representative   examples   of   how   BBB-crossing   is   addressed  in   these 
 
351conditions are discussed in the next sections. 
 








Therapeutic     approaches    to     neurodegenerative     diseases     are
 
355concentrating most of the efforts on the design of therapeutic compounds able 
 
356to cross the  BBB. For Parkinson's disease,  the  first  drug  used clinically was 
 
357the dopamine precursor L-Dopa, that contrarily to dopamine itself, crosses the 
 
358BBB by using  a large amino acid  transporter (Wade  and  Katzman 1975).  On 
 
359the  other  hand, in  a  Trojan  Horse  approach, Pardridge’s  group  normalized 
 
360striatal   tyrosine    hydroxylase   levels   and   reversed  functional   signs  in   a 
 
361Parkinson  model.  A tyrosine   hydroxylase  gene  empowered by  a  nervous 
 
362system-specific   promoter  was  injected,   carried    by   pegylated   liposomes 
 
363decorated with  OX26  antibody  against  TfR (Zhang  et  al.  2003;  Zhang  et  al. 
 
3642004a). The  team   was also  successful  entering  erythropoietin  (Zhou  et  al. 
 
3652011b)   and  glial  derived  neurotrophic  factor  (GDNF)  (Fu  et  al.  2010a)  by 
 
366joining    these   therapeutic    proteins    to    mice    anti-TfR    antibodies,    and 
 




Regarding Alzheimer, again, by means of this anti-TfR antibody as BBB
 
369transporter and  by fusion to an anti-Abeta amyloid antibody, the levels of beta 
 
370amyloid   peptide   were   dramatically  reduced  (Zhou   et  al.   2011a).  In  this 
 
371context,  Genentech is developing a lower affinity variant  of anti-TfR antibody 
 
372(that  favors  release  from  the  BBB towards the  CNS)  fused  to  an  antibody 
 
373against the enzyme BACE1, involved in amyloidal plaque formation. When the 
 
374bifunctional  molecule is  applied  systemically,  a decrease of 47 % in  plaques 
 
375was observed in mouse models (Yu et al. 2011).  Interestingly, the fusion of a 
 
376monovalent sFab of an  anti-TfR antibody to an  anti-Abeta antibody mediated 
 
377effective uptake transcytosisand TfR recycling, while the presence of two Fab 
 
378fragments onthe  anti-Abeta antibody resulted in uptake followed by trafficking 
 
379to  lysosomes  and  an  associated reduction  in  TfR  levels(Niewoehner  et  al, 
 
3802014).  This  approach exhibited  enhanced in  vivo  targeting  of Abeta  plaques 
 
381after  i.v.  administration.  Nerve   growth   factor  (NGF)  fused  to  an   anti-TfR 
 
382antibody  has also  been used successfully  to prevent neuronal  degeneration 
 
383when  applied  intravenously  in  a  Huntington  disease  model  (Kordower  et  al. 
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385with a rabies virus glycoprotein is able to ameliorates Alzheimer symptoms by 
 
386transporting  a  therapeutic  RNAi  (Park,   2015).   Alternatively,  the  intranasal 
 
387route  to  the  CNS  (Hanson and  Frey  2008),   through   the  olfactory  via  and 
 
388trigeminal  nerve  has been largely  explored  to introduce  important  factors  in 
 
389neurogenesis and  memory  such  as NGF (De et al. 2005),  insulin-like growth 
 
390factor 1 (IGF- I) (Liu et al. 2004),  fibroblast growth factor 2 (FGF-2)  (Jin et al. 
 
3912003),  insulin  (Benedict  et  al.  2004),  interferon  beta  (IFN beta   (Ross et  al. 
 
3922004)  and  the  octapeptide  NAP (Matsuoka et al.  2008)  which  is  currently in 
 










Diverse  BBB-crossing  anti-tumor  vectors  are   under   development  in
 
398both  pre-clinical  and   clinical  phases,  empowered by  a  spectrum  of  BBB- 
 
399crossing tags.  Angiochem  Inc.  entered into  Phase I  clinical  trials  a  product 
 
400(ANG1005)  that  uses the  peptide  Angiopep-2,  capable  of driving  the  cargo 
 
401paclitaxel by transcytosis through  the BBB by using  the LDL receptor LRP- 1. 
 
402This  conjugate  showed  previously  intracranial  tumor  regression  in  murine 
 
403models  when  administered  i.v.  (Bichat  2008).   Melanotransferrin  associated 
 
404with   doxorubicin   increased   the   survival   in   mice   with   intracranial   tumors 
 
405(Gabathuler 2005;  Karkan  et al. 2008).  Albumin is being used at University of 
 
406California,  San  Francisco  (UCSF),  in  a  Phase I  clinical  trial  as a  carrier  of 
 
407paclitaxel (nab-  paclitaxel) to treat  brain and  CNS  tumors  (Chien et al. 2009) 
 
408(it is  already  in  the  market  for breast cancer). Targeting  the  transmembrane 
 
409protein  TMEM30A,  the  ligand  FC5  (discovered  by  phage display,  a  single 
 
410domain  antibody  –  sdAb-),   drives  liposomes  though   the   BBB  to  release 
 
411doxorubicin  into  CNS  (Gabathuler  2010a). On  the  other  hand, by  taking  a 
 
412Trojan Horse  strategy based on pegylated immunoliposomes targeted to TfR 
 
413(Boado  et  al.  2007),  the  delivery  of shRNAs  expression vectors against  the 
 
414epidermal  growth  factor  receptor (EGFR)  increased the  survival  in mice  with 
 
415intracranial   tumors   (Boado   2007;   Pardridge   2004;   Zhang   et   al.   2004b). 
 
416Doxorubicin  ferried  by  polysorbate-coated  polymer  nanoparticles  promoted 
 
417long-term  glioblastoma  remission  in  rats,   probably  by  an   unspecific  BBB 
 
418crossing  (Steiniger   et   al.   2004),   and   a   polycefin   polymer   variant   that 
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419specifically    targets   human   brain,    which    associated   to   antiangiogenic 
 
420oligonucleotides  inhibits  tumor  angiogenesis  and   improves  animal  survival 
 




On  the   other   hand,  despite  no  direct  CNS   targeting,  it  has  been
 
423possible  to  increase  the  intracranial  levels  of  anticancer  3'5'-dioctanoyl-5- 
 
424fluoro-2'deoxyuridine   (DO-FUdR),    by   incorporating   it   into   a   solid   lipid 
 
425nanoparticle    (Wang     et    al.    2002).     Furthermore,    when     administered 
 
426systemically, nude  phosphorothioate oligonucleotides against protein kinase C 
 
427alpha,  also  reduced intracranial  glioblastoma  tumor  size  and  doubled  mice 
 
428survival  time  (Yazaki  et  al.  1996).  On  the  basis  of these results,  a  phase II 
 
429clinical   trial   has  been  completed   (http://www.clinicaltrials.gov/ct2/results? 
 
430term=pkc-alpha).  In  a  more  recent example,  an  intravenously  injected  cell 
 
431penetrating peptide (LNP) decorating a polylysine-PEG gene vector  extended 
 








Anti-nociception  is  usually achieved  by methylation  (Hansen, Jr.  et al.
 
4361992)  or glycosylation (Polt et al. 1994)  of active molecules to stimulate their 
 
437penetrability into the CNS. On the other  hand, coupling human serum albumin 
 
438to  an  anti-TfR  permits  the  transport  of  loperamide  into  the  CNS  for  anti- 
 
439nociception effects  (Ulbrich et al. 2009).  The  same drug  is delivered into the 
 
440CNS   by  injecting   i.v.   a   poly(lactic-co-glycolic)   acid   (PLGA)  nanoparticle, 
 
441derivatized  with  the  peptide  H2N-Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser(O-β- 
 
442D-Glucose)-CONH2  (g7) (Tosi et al. 2007).  The analgesic dalargine joined to a 
 
443cationic cell-penetrating peptide (Syn–B)  increases brain uptake in two orders 
 
444of magnitude. This peptide crosses the BBB using  a nonspecific route,  that is, 
 
445without    association    with    a    receptor   (Rousselle    et    al.    2003).    Other 
 










Sequelae  of  cerebral  ischemia  can  be  lessened  by  CNS  deliver  of
 
451brain-derived  neurotrophic  factor  (BDNF)  (Wu  and  Pardridge  1999;  Zhang 
 
452and  Pardridge  2001),   fibroblast  growth  factor  (FGF-2)   (Song   et  al.  2002), 
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453inhibitor of caspase-3 (Yemisci et al, 2014),  vasoactive intestinal peptide (VIP) 
 
454(Bickel et al. 1993;  Wu and  Pardridge 1996)  and  erythropoietin (EPO)  (Fu et 
 
455al. 2011)  linked to an  anti-TfR antibody. The  nerve  growth  factor (NGF) gene 
 
456has been introduced into the  CNS  while inside lipoplexes decorated with the 
 
457TfR natural  ligand,  transferrin  (da  Cruz  et al.  2005).  The  cell  penetrating Tat 
 
458peptide  has also  proven   to  carry  efficiently  N-methyl  D-aspartate receptor 
 
459subtype 2B (NR2B)  domain  (Aarts et  al.  2002),  B-cell  lymphoma-extra  large 
 
460protein (Bcl-XL) (Kilic et al. 2002),  glial cell-derived neurotrophic factor (GDNF) 
 
461(Kilic et al. 2003)  and  c-Jun  domain (Borsello et al. 2003),  to protect  neurons 
 
462in  brain  infarct  models.  On  the  other  side,  sniffing  insulin-like  growth  factor 
 
463(IGF-1)  (Liu  et  al.  2004)  and  EPO  (Yu  et  al.  2005)  protects brain  against 
 
464stroke   in  animal  models   (Hanson  and   Frey   2008).   Modular  protein/DNA 
 
465nanoparticles  have   been shown   to  induce  biologically  relevant  transgenic 
 
466protein  levels  and  therapeutic  effects  after  acute excytotoxic  injuries  when 
 
467injected  intracerebrally  (Negro-Demontel,et  al.,  2014;   Peluffo  et  al.  2003; 
 
468Peluffo  et  al.  2006;   Peluffo  et  al.  2011).   The   addition  of  CNS   targeting 
 










CNS infectious diseases have  also been treated in vivo using  different
 
474approaches. By  administering  i.v.  siRNA  into  Japanese encephalitis  virus- 
 
475infected mice,  Manjunath and  cols. afforded specific viral gene silencing and 
 
476protection.  The  siRNA  carrier   was  a  two-domain  peptide  formed  by  nine 
 
477arginines  (R9)  and  a  peptide  derived  from  rabies  virus  glycoprotein  (RVG) 
 
478(Kumar  et al. 2007).  On the  other  hand, the  brain levels of different anti HIV 
 
479drugs have  been increased several  folds through  association with liposomes 
 
480(foscarnet,   (Dusserre   et    al.    1995)),    micelles    (zidovudine,    lamivudine, 
 
481nelfinavir, (Spitzenberger et al. 2007))  and  the Tat protein (ritonavir, (Rao  et al. 
 
4822009)).   Furthermore, second  stage  African  trypanosomiasis   was  treated 
 
483intravenously in a mouse model by conjugating the  active water-soluble drug 
 




4866.6. Other conditions 
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487 Other   diseases  in  which  the   BBB  crossing has  been  successfully
 
488achieved  are  Hurler’s  Syndrome (mucopolysacharidosis),  using  the  mouse 
 
489anti-TfR  antibody  associated to  a  liposome  with  beta-glucuronidase  gene 
 
490(Zhang  et al. 2008)  or fusioned to the alpha-L-iduronidase enzyme (Boado  et 
 
491al.  2008).   A cell-penetrating  Tat  peptide  improves  the   beta-glucuronidase 
 
492biodistribution  when  organized  as a  single  chain  fusion  protein  (Xia et  al. 
 
4932001).   Narcolepsy   has  also   been  treated  with   good   results   with   nasal 
 










The   intravenous  administration  of  functionalized  nanoparticles  is  the
 
499most  used therapeutic route.  However, in some cases, patient compliance is 
 
500not   easy  to   achieve,   and   alternative   administration   routes  need  to   be 
 
501explored. In fact, there  are  standardized methods for drug delivery by osmotic 
 
502disruption (Kroll and  Neuwelt 1998; Yang et al. 2011),  by local delivery placing 
 
503polymer  wafers  after  tumor  excision   (Balossier  et  al.  2010),  by convection- 
 
504enhanced delivery  (White  et  al.  2012a; White  et  al.  2012b)  or by intranasal 
 
505administration (Grassin-Delyle et al. 2012;  Tsai 2012;  Wolf et al. 2012;  Zhu et 
 
506al. 2012)  (Figure 1 A). Some of these treatments are  still highly invasive and 
 
507are  only  addressed to  high  grade glioma  patients.  In  the  milder  intranasal 
 
508delivery, the drug is being accumulated in the olfactive bulb and  then  diffusing 
 
509inside  the  brain.  This  approach has been proven  to be  quite  effective  in  the 
 
510treatment of various disease  models,  acting  through   the  olfactory  pathway 
 
511and  trigeminal  nerve  (Born  et  al.  2002;  Hanson and  Frey  2008).  Regarding 
 
512gene therapy, only 1.9 % of current  clinical trials are  performed on the  CNS, 
 
513and  almost  all  of them  are  applied  by intracranial  injection  or performed ex 
 
514vivo  (Ginn  et  al.  2013),  pointing  to  the  importance  of the  delivery  of BBB- 
 




5178. Conclusions and future prospects 
 
518Numerous examples  of  basic  research and  ongoing  clinical  trials  illustrate 
 
519how proteins can  be engineered to overcome the complexity of both BBB and 
 
520BSCB  in  drug  delivery  contexts.  In  this  regard, a  few  CNS  diseases  are 
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521already   treated  with   protein-based   targeted  drugs,   and   much   more   are 
 
522expected to be  released  for use in  the  next  future.  Hopefully,  and  based on 
 
523current   insights  on  the   engineering  of  protein  self-assembling,  functional 
 
524proteins would be  desirably adapted as building blocks of nanosized entities, 
 
525acting at the  same time as BBB crossers, targeting agents and  drug  carriers. 
 
526Although  the  fully de  novo  design of such  protein-based artificial viruses is in 
 
527its infancy, the  accumulation of data  about  the  physiology of the  CNS  and  of 
 
528relevant  cell  receptors, the  widening  spectrum of drugs potentially  useful  in 
 
529CNS  therapies and  the  exploration of alternative routes for administration on 
 
530the bases of result from the use of natural viruses envisage the generation of 
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549Figure   1.  Anatomical   basis  of  the   BBB.  Boundaries   of  the   CNS   tissue 
 
550contacting   the   blood   vessels,   meninges   and   the   cerebrospinal   fluid  are 
 
551depicted  (A), and  also  alternative  routes for administration  of substances to 
 
552the   CNS   to   bypass  the   BBB.  The   intimate   relationship   between  ECs, 
 
553continuous   basement  membrane,  astrocytes,  pericytes   and   perivascular 
 
554macrophages  contributing  to  various  degrees   to  the   BBB  formation  and 
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555maintenance  can  be  observed (B). Moreover,  ependimocytes  of the  choroid 
 
556plexus  produce the  cerebrospinal  fluid  and  conform,  in  addition,  the  Blood 
 




559Figure   2.  Main  barriers  and   transport  mechanisms  of  the  BBB.  Physical 
 
560barriers  as endothelial  cell  membranes or intercellular  tight  junctions  are  the 
 
561principal  obstacles to overcome for polar  macromolecules  to enter  the  CNS 
 
562(left). Moreover,  intracellular and  extracellular enzymes, basal membrane and 
 
563astrocyte endfeet can  also constitute additional barriers. Endogenous protein 
 
564mediated  selective  transport  mechanisms  for  small  polar  substances  and 
 
565macromolecules  are  the  responsible  for the  communication  of the  CNS  with 
 
566the blood flow (right). These can  be exploited for targeted delivery of different 
 




569Figure  3. AAV9 administration  routes and  transduction  efficiencies.  Different 
 
570results  have  been obtained  when  AAV9 where  administered  by i.v.  or intra- 
 
571thecal delivery, but also in postnatal or adult animals, and  importantly in mice 
 
572or in non-human primates. While i.v. delivery efficiently transduce neurons and 
 
573astrocytes  in   postnatal   and   adult   mice,   very   low   efficiency   and   mainly 
 
574astrocyte  transduction   was  observed  in   non-human  primates.   Moreover, 
 
575intrathecal    delivery    into    the    Cisterna    Magna    resulted    in    the    widest 
 




578Figure  4. Receptor-mediated approaches used in Nanomedicine to cross the 
 
579BBB.     Different  types  of  proteins  (including  antibodies)  showing  specific 
 
580binding  to  BBB transporters and  cell  surface  receptors that  are  relevant  to 
 
581transcytosis are  used to  functionalize  nanoparticles  (NPs).  Cell-penetrating 
 
582peptides  carrying  therapeutic  proteins  are  also  depicted.  More  details  and 
 





















Table 1. Main transversal approaches to address  BBB-crossing in Nanomedicine, illustrated by representative examples.





conjugated to mAbs 








Carboxy  terminus of the  IgG heavy 
chain(mAb)     against     the     mouse 
transferrin receptor 
Monoclonal   antibodies   conjugated 
to polymeric micelles, liposomes 
(Mamot  et al. 2005a; Schnyder and 
Huwyler    2005a;    Ulbrich    et    al. 
2011b)  and  polymeric nanoparticles 
(Reukov     et    al.    2011b)     against 
insulin receptor 
Erythropoietin fused to the 
mAb to treat 
Stroke  (Fu et al. 2011) 
Insulin   or   an   anti-insulin 
 
receptor mAbs were 
covalently coupled to the 
Human  serum albumin NP 









chemical NPs to 
interact with LDLR 
LDLR               Apolipoproteins                                        Adsorption                         
of apolipoprotein B-100 
(ApoB-100) onto PEG- 




covalent binding of 
endogenous ligands 




THR derived peptide                               Gold               
nanoparticles conjugated 
to THR peptide target  
transferrin receptor and  
can  deliver  gold  NPs 
to the  CNS  (Prades et  al. 
519±10  nm
 












Lactoferrin                                                 Pegylated     Fe3O4        
NPS conjugated with 
lactoferrin used  for   
imaging diagnostic  
purposes (Qiao 


















589mAbs: monoclonal antibodies 
LDLR               Peptides    derived    from    ApoE20,29, 
ApoB23     and   ApoA-I  (Kratzer   et  al. 
2007b;  Lu et al. 2011a) 
 
 
LDLR               Peptides    originated    from    Kunitz 
protein (angiopeps) 
LDLR   binding-domain   of    ND 
ApoB    was   cloned     into 
lentivirus  vector   (Spencer 
and  Verma 2007a) 
Covalently bound  to drugs   ND 
 
used for  the  treatment of 
brain tumors (Demeule et 
al. 2008a)
590LDLR: low density  liproprotein receptor 
591Apo: apolipoprotein 
592NP: nanoparticle 
593ND: not determined 
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595Table 2: Disease-focused main approaches to BBB drug transdelivery. 
 
 




Parkinson                           L-Dopa                                 Large  amino acid 
 
transporter 
L-dopa                                                                      (Wade  and  Katzman 1975)
Tyrosine  hydroxylase 
 
gene                                TfR                                Pegylated liposome decorated with OX26 ab 
 
agains TfR.                                                              (Zhang  et al. 2003; Zhang  et al. 2 
Erythropoietin                      TfR                                Fusion  protein joined to TfR ab.                           (Zhou et al. 2011b) 
GDNF                                   TfR                                Fusion  protein joined to TfR ab.                           (Fu et al. 2010b) 
Alzheimer                              Ab against beta-amyloid   TfR                                Fusion  protein joined to TfR ab.                           (Zhou et al. 2011a) 
Ab against BACE1 
 
enzyme                            TfR                                Fusion  protein joined to low affinity TfR ab.       (Yu et al. 2011) 





ND                                Polycefin polymer                                                   (Ljubimova et al. 2008)
DO-FUdR                             ND                                Drug incorporated in solid lipid nanoparticles    (Wang  et al. 2002) 
LRP-1 (LDL
 





receptor)                    Drug conjugated to Angiopep-2 peptide.            (Bichat 2008) 
Melanotransferrin 
 
receptor                     Drug associated with Melanotransferrin             (Karkan et al. 2008)

















shRNAs against EGFR 
Insuline Receptor / 
Transferrine 
receptor 
LDL receptor via 
 
 
Pegylated immunolyposomes associated to 
 










protein kinase C alpha       ND                                Nude  oligonucleotide administration                   (Yazaki et al. 1996) 
 











PLGA nanoparticle derivatized with a 
 
glicosylated heptapeptide                                     (Tosi et al. 2007)







Dalargine                             TMEM30A 
transmembrane 
protein 




















BDNF                                   TfR                                Protein linked to TfR ab.                                        (Wu and  Pardridge 1999) 
FGF-2                                   TfR                                Protein linked to TfR ab.                                        (Song  et al. 2002) 
VIP                                        TfR                                Protein linked to TfR ab.                                        (Bickel et al. 1993) 
Erythropoietin                      TfR                                Protein linked to TfR ab.                                        (Fu et al. 2011) 
NGF gene                       TfR                                Lipoplexes decorated with transferrin                 (da Cruz et al. 2005) 
NR2B                                    ND                                Protein fused to cell penetrating peptide            (Aarts et al. 2002) 
Bcl-Xl                                     ND                                Protein fused to cell penetrating peptide            (Kilic et al. 2002) 
GDNF                                   ND                                Protein fused to cell penetrating peptide            (Kilic et al. 2003) 
JNKI                                      ND                                Protein fused to cell penetrating peptide            (Borsello et al. 2003) 
 











Drug associated to liposomes 
Drug associated to micelles 
Drug associated to cell penetrating peptide 
(Dusserre et al. 1995) 
(Spitzenberger et al. 2007) 
(Rao  et al. 2009) 
 LDL receptor via   
Diminazenediaceturate Apo E enrichement Lipid-drug conjugate (Gessner et al. 2001) 
Mucopolysacharidosis     
 Beta-glucuronidase    
 gene 
Alpha-L-iduronidase 
TfR Liposomes associated to TfR Ab. (Zhang  et al. 2008) 
 enzyme TfR Protein linked to TfR ab. (Boado  et al. 2008) 
 Beta-glucuronidase ND Protein fused to cell penetrating peptide (Xia et al. 2001) 
596ND: not determined 
597PLGA:  Poly(lactic-co-glycolic) acid 
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